Patent intelligence · US
US 12383503
Adagrasib solid pharmaceutical compositions
Adagrasib solid pharmaceutical compositions
Patent details — US 12383503
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 12, 2025
- Expiration
- Aug 7, 2045
- Applicant
- Mirati Therapeutics, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K31/519, A61K9/0053, A61K9/2009
Quick answer
US 12383503 (Adagrasib solid pharmaceutical compositions) is held by Mirati Therapeutics, Inc.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/519, A61K9/0053, A61K9/2009, A61K9/2013, A61K9/2018
More from Mirati Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Related coverage
KRAS G12C Inhibitors NSCLC: Market Analysis of Sotorasib & Adagrasib
This article delves into the market dynamics of KRAS G12C inhibitors, Sotorasib and Adagrasib, highlighting their roles in non-small cell lung cancer treatment.
Adagrasib Phase 3 Trial Results: Key Insights on KRAS G12C NSCLC
The Phase 3 trial results of Adagrasib highlight its promising efficacy in treating KRAS G12C NSCLC, offering new hope for patients with this challenging cancer.
FDA Approval KRAS G12C NSCLC: Sotorasib & Adagrasib Insights
Explore the latest insights on FDA-approved Sotorasib and Adagrasib for treating KRAS G12C NSCLC, transforming lung cancer therapy.
FDA Accelerated Approval of KRAS G12C Inhibitors in NSCLC: Sotorasib vs Adagrasib
This article delves into the FDA's accelerated approval of KRAS G12C inhibitors, Sotorasib and Adagrasib, highlighting their impact on NSCLC treatment.
Frequently asked questions
What is US patent 12383503?
US 12383503 (Adagrasib solid pharmaceutical compositions) is held by Mirati Therapeutics, Inc.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12383503?
Mirati Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 12383503 expire?
Our index shows an expiration date of Aug 7, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.